Interferon A and B Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global interferon a and b market is anticipated to grow at a significant CAGR during the forecast period. Interferon refers to a natural substance that assists the body’s immune system fight infection and other diseases such as cancers. The rise in the prevalence of cancers such as kidney cancer, and lung cancers among others is one of the factors driving the growth of the global interferon a and b market. For instance, according to the data published by the American Cancer Society (ACS) in 2022, approximately 13.0% of all lung cancers are SCLC and, 84.0% are non-small cell lung cancer (NSCLC). Moreover, lung cancer is the leading cause of mortality in both men and women accounting for 25.0% of all cancer mortalities.

Looking towards the demand for interferon a and b, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, Betterlife Pharma had agreed with List Biological Laboratories Inc. (List Labs) to manufacture interferon-alpha 2b (AP003) for the treatment of COVID-19. As per the terms of the agreement, List Labs will provide manufacturing services from its state of art biological development and cGMP manufacturing facility in Campbell. Further, in September 2020, the company had received clearance from Financial Industry Regulatory Authority to trade the company’s securities in OTC markets.

Moreover, in October 2020, Betterlife Pharma announced the partnership with VirTrial LLC to conduct patient monitoring for its COVID-19 clinical trials to test the efficacy of AP-003. Moreover, in April 2020, Bayer AG partnered with Population Health Research Institute (PHRI) to launch a clinical research program to identify potential treatments against COVID-19. The study aimed to evaluate the combination of chloroquine with azitromycin as well as Interferon Beta -1b, to prevent admission to the intensive care unit (ICU) to combat COVID-19. Thus, such strategic collaborations are anticipated to drive the growth of the global interferon a and b market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis International AG, Merck & Co, and Zydus Cadila among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Interferon a and b Market Report by Segment

By Type

• 1000 IU
• 4000 IU
• 1 Million IU
• 3 Million IU
• 5 Million IU
• 6 Million IU
• 20000 IU

By Application

• Recombinant Interferon
• Recombinant Interleukin
• Natural Biological Products
• Poison Immune
• Gene Therapy
• Monoclonal Antibody